ProCE Banner Activity

Real-World Challenges With MEK Inhibitors for NF1-Related Plexiform Neurofibromas

Clinical Thought
A neurofibromatosis expert shares his perspective on key issues faced by clinicians using MEK inhibitors to manage patients with neurofibromatosis 1, such as assessing response, determining the optimal duration of therapy, and improving tolerability.

Released: August 02, 2021

Expiration: August 01, 2022

Share

Faculty

Scott Plotkin

Scott Plotkin, MD, PhD

Professor of Neurology
Division of Neuro-Oncology
Harvard Medical School
Neurologist
Department of Neurology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Scott Plotkin, MD, PhD

Professor of Neurology
Division of Neuro-Oncology
Harvard Medical School
Neurologist
Department of Neurology
Massachusetts General Hospital
Boston, Massachusetts

Scott R. Plotkin, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Akouos, and SonALAsense and has ownership interest in NFlection and NF2 Therapeutics.